Novo Nordisk's Q1 2026 earnings (released May 6) confirm what IQVIA prescription data already hinted at — the Wegovy pill is dominating the oral GLP-1 race. Oral Wegovy now serves more than 1 million patients since its January launch. Lilly's Foundayo (orforglipron), which launched April 1, logged just 3,707 prescriptions in its second week — roughly five times fewer than oral Wegovy at the same stage.
The numbers
Oral Wegovy (Novo Nordisk, semaglutide 25 mg pill):
- Launched: January 5, 2026
- Q1 2026 revenue: lifted Novo Nordisk's total sales 32% to 96.8 billion DKK ($15.2 billion)
- Patients on therapy: more than 1 million as of early May
- US new-Rx share for the broader Wegovy brand: 65%
- Novo hiked full-year guidance on the back of pill momentum
Foundayo (Lilly, orforglipron — small-molecule oral GLP-1):
- Launched: April 1, 2026 (LillyDirect first, retail pharmacies + Amazon Pharmacy from April 9)
- Week 2 IQVIA prescription count: 3,707
- Analyst target for 2026: 5–6 million scripts to hit ~$2 billion in launch-year sales
- Investor reaction: LLY stock pressure post-earnings, mostly tied to Foundayo's modest start versus Mounjaro/Zepbound's continued dominance (source)
The gap matters because both pills target the same patient — the GLP-1 candidate who wants the convenience of a tablet. Doctors prescribing one over the other are making a side-by-side choice. So far, that choice is going to Novo.
Why oral Wegovy is winning
Earlier launch, deeper payer integration. Novo had three months of head start. By the time Foundayo hit shelves, oral Wegovy was already on most major formularies, prior-auth pathways were established, and prescribers had a workflow.
Higher mean weight loss in the head-to-head data. Oral Wegovy 25 mg produced 16.6% mean weight loss in OASIS 4 (source). Orforglipron in ATTAIN-1 produced 7.5–11.2% depending on dose. When both pills cost the same, patients and prescribers pick the one that produced better Phase 3 numbers.
Brand recognition. "Wegovy pill" is a known brand. "Foundayo" is a new name that Lilly is still building consumer awareness around. The Wegovy injectable script base gave Novo an instant audience to convert.
Different molecules, different ceilings. Oral Wegovy is a peptide (semaglutide) absorbed through SNAC-permeated gastric uptake — same molecule as the injection. Orforglipron is a small molecule built to dodge peptide-absorption problems entirely, which solved the bioavailability issue but appears to have traded away receptor potency. The clinical data reflects this trade-off.
What this means for buyers
If you're choosing between the two branded oral GLP-1 pills:
- Insurance covers Wegovy at $25/mo: Stay on oral Wegovy. The clinical data is stronger and the supply chain is established.
- Cash-pay $149–$299/mo on either pill: Wegovy still has a slight edge on price-per-percent-weight-loss given the higher mean reduction.
- Insurance covers Foundayo but not Wegovy: Foundayo is still a meaningful weight-loss tool — 7.5–11.2% mean reduction is well above placebo. Use it.
If you're a research-peptide buyer comparing branded oral pills against compounded or research-grade injectable peptides, the math gets more interesting. Compounded semaglutide typically runs $129–$299/mo at therapeutic doses and uses the same molecule as the injectable Wegovy that delivers ~15% mean weight loss in STEP 1. Research-grade tirzepatide and retatrutide vials price out lower per milligram and produce stronger Phase 3 numbers (20–28% mean weight loss).
The Wegovy pill's launch momentum doesn't change that calculus — it just confirms that demand for oral GLP-1s is real, and that branded prices are sticking even as patients pile in.
For peptide buyers ready to source vials directly, the best retatrutide vendors, tirzepatide vendor list, and semaglutide vendors cover live pricing, COA status, and active discounts. Vendor-side coupons and bulk pricing live on /deals.
